Skip to content

Pituitary Gland Stimulation for Cancer Pain Relief

Pituitary Gland Stimulation for Cancer Pain Relief

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05230238
Acronym
PGS
Enrollment
10
Registered
2022-02-08
Start date
2021-10-12
Completion date
2024-01-01
Last updated
2023-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology Pain

Brief summary

Patients will undergo an implantation of an extradural pituitary surface electrode in the pituitary fossa. The electrode will be attached to a neurostimulator via which the patient will receive up to 8 (patient requested) stimulations per day.

Interventions

DEVICEPituitary gland stimulation

Pituitary gland stimulation via an surface electrode connected to an external neurostimulator

Sponsors

Leiden University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient * In palliative phase of metastatic disease, without options for further systemic treatment or radiotherapy * Inadequately controlled pain with standard care * Most prominent part of experienced pain is nociceptive * Karnofsky Performance Score ≥30

Exclusion criteria

* Not fit for general anesthesia * Pregnancy * Unfavorable local anatomy for PGS, due to a disease process, or anatomical configuration * Clinical signs of posterior pituitary gland disfunction * Recent history of alcohol or drug abuse * Severe immunodeficiency * Need for anticoagulation therapy that cannot be abrogated for surgery * Need for subsequent MRI-imaging * Cognitive impairments prohibiting full understanding of study and ability to provide informed consent * Not able to adequately communicate in Dutch or English

Design outcomes

Primary

MeasureTime frameDescription
Perceived pain4 monthsNumeric Rating Scale (0= no pain, 10=most severe pain)
Pain Medication4 monthsMorphine Equivalent Doses for background and escape medication

Countries

Netherlands

Contacts

Primary ContactWouter van Furth, MD, Phd
w.r.van_furth@lumc.nl+31715162109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026